Document is current
Any future updates will be listed below
-
Authors
Lu, I-Na
Dobersalske, Celia https://orcid.org/0000-0003-4233-102X
Rauschenbach, Laurèl https://orcid.org/0000-0001-8348-4298
Teuber-Hanselmann, Sarah
Steinbach, Anita
Ullrich, Vivien
Prasad, Shruthi
Blau, Tobias
Kebir, Sied
Siveke, Jens T.
Becker, Jürgen C.
Sure, Ulrich
Glas, Martin
Scheffler, Björn https://orcid.org/0000-0001-8316-6556
Cima, Igor https://orcid.org/0000-0002-6196-6971
-
Funding
Funding for this research was provided by:
Wilhelm Sander-Stiftung (2017.148.1, 2017.148.1)
Deutsche Forschungsgemeinschaft (DFG/GRC-CRU337 (SCHE656/2-1))
- License Information
-
More Information
Article History
Received: 6 April 2020
Accepted: 28 May 2021
First Online: 23 June 2021
Competing interests
: J.T.S.: Bristol-Myers Squibb, Celgene, Roche (Research Funding - outside of this study); AstraZeneca, Bristol-Myers Squibb, Celgene, Immunocore, Novartis, Roche, Shire (Consulting or advisory role); AstraZeneca, Aurikamed, Baxalta, Bristol-Myers Squibb, Celgene, Falk Foundation, iomedico, Immunocore, Novartis, Roche, Shire (honoraria); minor equity in FAPI Holding and Pharma15 (<3%) and member of the Board of Directors for Pharma15 outside the submitted work. All other authors declare no competing interests.
